Fredun Pharmaceuticals Ltd
BSE:539730
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Fredun Pharmaceuticals Ltd
BSE:539730
|
IN |
|
T
|
Tianjin Capital Environmental Protection Group Co Ltd
SSE:600874
|
CN |
Balance Sheet
Balance Sheet Decomposition
Fredun Pharmaceuticals Ltd
Fredun Pharmaceuticals Ltd
Balance Sheet
Fredun Pharmaceuticals Ltd
| Mar-2014 | Mar-2015 | Mar-2016 | Mar-2017 | Mar-2018 | Mar-2019 | Mar-2020 | Mar-2021 | Mar-2022 | Mar-2023 | Mar-2024 | Mar-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||||
| Cash & Cash Equivalents |
4
|
6
|
14
|
8
|
15
|
15
|
31
|
11
|
21
|
39
|
6
|
46
|
|
| Cash |
0
|
0
|
0
|
0
|
0
|
15
|
31
|
11
|
21
|
34
|
3
|
46
|
|
| Cash Equivalents |
4
|
6
|
14
|
8
|
15
|
0
|
0
|
0
|
0
|
5
|
3
|
0
|
|
| Short-Term Investments |
0
|
0
|
0
|
0
|
78
|
0
|
21
|
9
|
1
|
128
|
42
|
65
|
|
| Total Receivables |
36
|
55
|
117
|
214
|
153
|
302
|
391
|
418
|
911
|
491
|
752
|
1 778
|
|
| Accounts Receivables |
34
|
52
|
114
|
204
|
153
|
178
|
390
|
411
|
903
|
346
|
648
|
1 771
|
|
| Other Receivables |
2
|
3
|
3
|
10
|
1
|
124
|
2
|
7
|
9
|
145
|
104
|
6
|
|
| Inventory |
36
|
43
|
103
|
69
|
184
|
408
|
505
|
676
|
465
|
1 501
|
1 750
|
2 399
|
|
| Other Current Assets |
23
|
27
|
49
|
62
|
85
|
1
|
146
|
187
|
129
|
8
|
14
|
32
|
|
| Total Current Assets |
100
|
131
|
283
|
352
|
515
|
725
|
1 093
|
1 301
|
1 526
|
2 162
|
2 572
|
4 280
|
|
| PP&E Net |
70
|
93
|
145
|
205
|
274
|
314
|
310
|
304
|
323
|
386
|
462
|
525
|
|
| PP&E Gross |
0
|
0
|
0
|
0
|
0
|
314
|
310
|
304
|
323
|
386
|
462
|
525
|
|
| Accumulated Depreciation |
0
|
0
|
0
|
0
|
0
|
38
|
58
|
76
|
98
|
124
|
161
|
273
|
|
| Intangible Assets |
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
3
|
4
|
4
|
|
| Note Receivable |
5
|
5
|
0
|
4
|
0
|
5
|
5
|
5
|
13
|
16
|
19
|
20
|
|
| Long-Term Investments |
0
|
0
|
0
|
0
|
4
|
6
|
6
|
7
|
0
|
0
|
5
|
12
|
|
| Other Long-Term Assets |
2
|
1
|
1
|
0
|
0
|
0
|
0
|
0
|
7
|
5
|
15
|
33
|
|
| Total Assets |
177
N/A
|
230
+30%
|
432
+88%
|
561
+30%
|
793
+41%
|
1 049
+32%
|
1 414
+35%
|
1 616
+14%
|
1 870
+16%
|
2 573
+38%
|
3 076
+20%
|
4 874
+58%
|
|
| Liabilities | |||||||||||||
| Accounts Payable |
51
|
70
|
163
|
228
|
389
|
337
|
462
|
600
|
486
|
593
|
629
|
1 448
|
|
| Accrued Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
13
|
18
|
18
|
20
|
18
|
30
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
86
|
234
|
105
|
107
|
677
|
868
|
1 506
|
|
| Current Portion of Long-Term Debt |
44
|
51
|
69
|
76
|
0
|
0
|
0
|
0
|
0
|
34
|
60
|
82
|
|
| Other Current Liabilities |
26
|
41
|
88
|
101
|
42
|
111
|
151
|
142
|
126
|
72
|
94
|
216
|
|
| Total Current Liabilities |
121
|
162
|
319
|
405
|
431
|
534
|
860
|
865
|
738
|
1 397
|
1 668
|
3 281
|
|
| Long-Term Debt |
20
|
29
|
62
|
72
|
0
|
106
|
115
|
291
|
420
|
154
|
128
|
96
|
|
| Deferred Income Tax |
5
|
5
|
7
|
8
|
8
|
8
|
9
|
14
|
14
|
38
|
41
|
45
|
|
| Other Liabilities |
2
|
2
|
4
|
3
|
132
|
11
|
16
|
16
|
17
|
20
|
24
|
38
|
|
| Total Liabilities |
148
N/A
|
199
+35%
|
392
+97%
|
488
+24%
|
571
+17%
|
659
+15%
|
1 001
+52%
|
1 185
+18%
|
1 189
+0%
|
1 609
+35%
|
1 861
+16%
|
3 460
+86%
|
|
| Equity | |||||||||||||
| Common Stock |
26
|
26
|
26
|
49
|
34
|
311
|
311
|
311
|
498
|
45
|
47
|
47
|
|
| Retained Earnings |
2
|
5
|
13
|
24
|
187
|
78
|
102
|
119
|
182
|
369
|
453
|
639
|
|
| Additional Paid In Capital |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
550
|
714
|
728
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Equity |
29
N/A
|
31
+8%
|
40
+28%
|
73
+83%
|
222
+205%
|
390
+76%
|
413
+6%
|
431
+4%
|
681
+58%
|
964
+42%
|
1 215
+26%
|
1 414
+16%
|
|
| Total Liabilities & Equity |
177
N/A
|
230
+30%
|
432
+88%
|
561
+30%
|
793
+41%
|
1 049
+32%
|
1 414
+35%
|
1 616
+14%
|
1 870
+16%
|
2 573
+38%
|
3 076
+20%
|
4 874
+58%
|
|
| Shares Outstanding | |||||||||||||
| Common Shares Outstanding |
2
|
2
|
2
|
2
|
3
|
4
|
4
|
4
|
4
|
5
|
5
|
5
|
|